Neoleukin Therapeutics Inc (NGNE) 26.95 USD (+0.00%)

Neoleukin Therapeutics Inc is dedicated to the development of innovative immunotherapies for cancer and autoimmune diseases.

Price history of Neoleukin Therapeutics Inc

Performance & Momentum

6 Months 32.77 %

1 Year 65.76 %

3 Years 69.43 %

5 Years 85.72 %

Momentum

Unlock this indicator

Strategic Analysis

Neoleukin Therapeutics Inc • 2026

Neoleukin Therapeutics is a small U.S. biotech focused on oncology and innovative therapies, with an approach based on engineered therapeutic proteins designed to address significant medical needs. Its positioning remains that of a specialized research company, potentially differentiated from a scientific standpoint, but dependent on the success of its clinical programs and the step-by-step creation of value.

Strengths

Exposure to oncology, an attractive segment where substantial value can be created if clinical validation is achieved
Positioning in innovative therapies, which could lead to scientific differentiation versus more conventional approaches
Stock momentum remains supported over the recent period, indicating continued speculative interest from the market

Weaknesses

Small biotech profile highly dependent on trial results, with elevated binary risk
Very weak long-term performance history, reflecting difficult value creation and high volatility

Momentum

Current momentum appears positive but choppy: the stock is still benefiting from a recent pickup in interest, without erasing an unstable underlying trend. For investors, this suggests more of a special situation than a defensive quality name, with re-rating potential tied to pipeline catalysts but a significant risk of reversal if clinical validation fails.

Analysis performed 1 month ago